Human Bone Marrow-derived Mesenchymal Stem Cell-secreted Exosomes Overexpressing MicroRNA-34a Ameliorate Glioblastoma Development Via Down-regulating MYCN

Overview

Journal Cell Oncol (Dordr)

Publisher Springer

Date 2019 Jul 24

PMID 31332647

Citations 30

Authors

Bin Wang

Zhong-Hua Wu

Ping-Yang Lou

Chang Chai

Shuang-Yin Han

Jian-Fang Ning

Ming Li

Affiliations

Soon will be listed here.

Abstract

Purpose: Exosomes play important roles in intercellular communication through signaling pathways affecting tumor microenvironment modulation and tumor proliferation, including those in glioblastoma (GBM). As yet, however, limited studies have been conducted on the inhibitory effect of human bone marrow-derived mesenchymal stem cell (hBMSC)-derived exosomes on GBM development. Therefore, we set out to assess the role of hBMSC secreted exosomes, in particular those carrying microRNA-34a (miR-34a), in the development of GBM.

Methods: Microarray-based expression analysis was employed to identify differentially expressed genes and to predict miRNAs regulating MYCN expression. Next, hBMSCs were transfected with a miR-34a mimic or inhibitor after which exosomes were isolated. Proliferation, apoptosis, migration, invasion and temozolomide (TMZ) chemosensitivity of exosome-exposed GBM cells (T-98G, LN229 and A-172) were measured in vitro. The mechanism underlying MYCN regulation was investigated using lentiviral transfections. The in vivo inhibitory effect of exosomal miR-34a was measured in nude mice xenografted with GBM cells through subcutaneous injection of hBMSCs with an upregulated miR34a content.

Results: We found that poorly-expressed miR-34a specifically targeted and negatively regulated the expression of MYCN in GBM cells. In addition we found that miR-34a was delivered to T-98G, LN229 and A-172 GBM cells via hBMSC-derived exosomes. Exogenous overexpression of miR-34a in hBMSC-derived exosomes resulted in inhibition of GBM cell proliferation, invasion, migration and tumorigenesis in vitro and in vivo, while promoting the chemosensitivity of GBM cells to TMZ by silencing MYCN.

Conclusions: From our data we conclude that hBMSC-derived exosomes overexpressing miR-34a may be instrumental for the therapeutic targeting and clinical management of GBM.

Citing Articles

Exploring the clinical implications and applications of exosomal miRNAs in gliomas: a comprehensive study.

Yang L, Niu Z, Ma Z, Wu X, Vong C, Li G Cancer Cell Int. 2024; 24(1):323.

PMID: 39334350 PMC: 11437892. DOI: 10.1186/s12935-024-03507-x.

From bench to bedside: The promising value of exosomes in precision medicine for CNS tumors.

Wang M, Jin F, Tong X Heliyon. 2024; 10(11):e32376.

PMID: 38961907 PMC: 11219334. DOI: 10.1016/j.heliyon.2024.e32376.

Hypoxic Bone Mesenchymal Stem Cell-Derived Exosomes Direct Schwann Cells Proliferation, Migration, and Paracrine to Accelerate Facial Nerve Regeneration via circRNA_Nkd2/miR-214-3p/MED19 Axis.

Wang H, Zhao H, Chen Z, Cai X, Wang X, Zhou P Int J Nanomedicine. 2024; 19:1409-1429.

PMID: 38371458 PMC: 10871042. DOI: 10.2147/IJN.S443036.

The role of mesenchymal stem cells derived exosomes as a novel nanobiotechnology target in the diagnosis and treatment of cancer.

Zhou Y, Dong Y, Zhang A, Wu J, Sun Q Front Bioeng Biotechnol. 2023; 11:1214190.

PMID: 37662434 PMC: 10470003. DOI: 10.3389/fbioe.2023.1214190.

Cell-based and cell-free immunotherapies for glioblastoma: current status and future directions.

Wang M, Wang X, Jin X, Zhou J, Zhang Y, Yang Y Front Immunol. 2023; 14:1175118.

PMID: 37304305 PMC: 10248152. DOI: 10.3389/fimmu.2023.1175118.

References

Niu C, Yang Y, Cheng C . MiR-134 regulates the proliferation and invasion of glioblastoma cells by reducing Nanog expression. Int J Oncol. 2013; 42(5):1533-40. PMC: 3661226. DOI: 10.3892/ijo.2013.1844. View

Nicholas M, Lukas R, Chmura S, Yamini B, Lesniak M, Pytel P . Molecular heterogeneity in glioblastoma: therapeutic opportunities and challenges. Semin Oncol. 2011; 38(2):243-53. DOI: 10.1053/j.seminoncol.2011.01.009. View

Thor T, Kunkele A, Pajtler K, Wefers A, Stephan H, Mestdagh P . MiR-34a deficiency accelerates medulloblastoma formation in vivo. Int J Cancer. 2014; 136(10):2293-303. DOI: 10.1002/ijc.29294. View

Bjerke L, Mackay A, Nandhabalan M, Burford A, Jury A, Popov S . Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer Discov. 2013; 3(5):512-9. PMC: 3763966. DOI: 10.1158/2159-8290.CD-12-0426. View

Lehrer S . Glioblastoma and dementia may share a common cause. Med Hypotheses. 2010; 75(1):67-8. DOI: 10.1016/j.mehy.2010.01.031. View

Wang J, Hendrix A, Hernot S, Lemaire M, de Bruyne E, Van Valckenborgh E . Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells. Blood. 2014; 124(4):555-66. DOI: 10.1182/blood-2014-03-562439. View

Shohet J, Ghosh R, Coarfa C, Ludwig A, Benham A, Chen Z . A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma. Cancer Res. 2011; 71(11):3841-51. DOI: 10.1158/0008-5472.CAN-10-4391. View

Xu M, Li D, Yang C, Ji J . MicroRNA-34a Inhibition of the TLR Signaling Pathway Via CXCL10 Suppresses Breast Cancer Cell Invasion and Migration. Cell Physiol Biochem. 2018; 46(3):1286-1304. DOI: 10.1159/000489111. View

Sumazin P, Yang X, Chiu H, Chung W, Iyer A, Llobet-Navas D . An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma. Cell. 2011; 147(2):370-81. PMC: 3214599. DOI: 10.1016/j.cell.2011.09.041. View

10.

Xu J, Huang H, Peng R, Ding X, Jiang B, Yuan X . MicroRNA-30a increases the chemosensitivity of U251 glioblastoma cells to temozolomide by directly targeting beclin 1 and inhibiting autophagy. Exp Ther Med. 2018; 15(6):4798-4804. PMC: 5952084. DOI: 10.3892/etm.2018.6007. View

11.

Umezu T, Imanishi S, Azuma K, Kobayashi C, Yoshizawa S, Ohyashiki K . Replenishing exosomes from older bone marrow stromal cells with miR-340 inhibits myeloma-related angiogenesis. Blood Adv. 2018; 1(13):812-823. PMC: 5727805. DOI: 10.1182/bloodadvances.2016003251. View

12.

Yin D, Ogawa S, Kawamata N, Leiter A, Ham M, Li D . miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme. Oncogene. 2012; 32(9):1155-63. PMC: 4085050. DOI: 10.1038/onc.2012.132. View

13.

Shatsberg Z, Zhang X, Ofek P, Malhotra S, Krivitsky A, Scomparin A . Functionalized nanogels carrying an anticancer microRNA for glioblastoma therapy. J Control Release. 2016; 239:159-68. DOI: 10.1016/j.jconrel.2016.08.029. View

14.

Hata N, Shinojima N, Gumin J, Yong R, Marini F, Andreeff M . Platelet-derived growth factor BB mediates the tropism of human mesenchymal stem cells for malignant gliomas. Neurosurgery. 2009; 66(1):144-56. PMC: 2811094. DOI: 10.1227/01.NEU.0000363149.58885.2E. View

15.

Lages E, Guttin A, El Atifi M, Ramus C, Ipas H, Dupre I . MicroRNA and target protein patterns reveal physiopathological features of glioma subtypes. PLoS One. 2011; 6(5):e20600. PMC: 3105101. DOI: 10.1371/journal.pone.0020600. View

16.

Chen Y, Tsai Y, Tseng S . Inhibition of cyclin-dependent kinase 1-induced cell death in neuroblastoma cells through the microRNA-34a-MYCN-survivin pathway. Surgery. 2012; 153(1):4-16. DOI: 10.1016/j.surg.2012.03.030. View

17.

Kondo N, Takahashi A, Mori E, Noda T, Zdzienicka M, Thompson L . FANCD1/BRCA2 plays predominant role in the repair of DNA damage induced by ACNU or TMZ. PLoS One. 2011; 6(5):e19659. PMC: 3090409. DOI: 10.1371/journal.pone.0019659. View

18.

Savina A, Furlan M, Vidal M, Colombo M . Exosome release is regulated by a calcium-dependent mechanism in K562 cells. J Biol Chem. 2003; 278(22):20083-90. DOI: 10.1074/jbc.M301642200. View

19.

Li W, Ma M, Dong L, Wang F, Chen L, Li X . MicroRNA-34a targets notch1 and inhibits cell proliferation in glioblastoma multiforme. Cancer Biol Ther. 2011; 12(6):477-83. DOI: 10.4161/cbt.12.6.16300. View

20.

Wang J, Cazzato E, Ladewig E, Frattini V, Rosenbloom D, Zairis S . Clonal evolution of glioblastoma under therapy. Nat Genet. 2016; 48(7):768-76. PMC: 5627776. DOI: 10.1038/ng.3590. View